Roche FY24 Core Operating Profit Rises; Sales Up 7% At CER
Roche (RHHBY) reported that its fiscal 2024 IFRS net income decreased by 19%, or 26% in Swiss francs, to 9.2 billion francs, mainly ...
Roche Expects Sales, Earnings Growth After Better-Than-Expected Results
The pharmaceutical giant said for 2025 it anticipates sales growth in the mid-single-digit range at constant exchange rates, ...
Roche sees high single-digit core profit growth in 2025
Roche said on Thursday it is targeting a continued increase in adjusted earnings per share (EPS) at a high single-digit percentage this year, helped by lower costs and growth from drugs such as eye ...
Royalty Pharma Announces Sale of MorphoSys Development Funding Bonds
Total proceeds of $530 million on $300 million original 2022 investment Proceeds strengthen balance sheet and provide added flexibility to pursue ...
Roche receives FDA 510(k) clearance for the first blood test in the U.S. measuring Lp(a) in molar units
Gen.2 Molarity assay has received 510(k) clearance from the United States Food and Drug Administration (FDA). This will be the first 510(k) cleared test of its kind available in the U.S. measuring ...